Targeted therapies in gynecologic cancers and melanoma.
The article reviews the main molecular pathology alterations of endometrial and ovarian carcinomas and melanoma. Several promising drugs targeting the genes most frequently altered in these tumors are under consideration. The most promising signaling pathways to be targeted for therapies in these tumors are the tyrosine kinase receptor (EGFR, HER2, c-KIT), the RAS/B-RAF/MAPK, the PI3K-mTOR, and apoptosis signaling pathways.
Ortega
Eugenia
E
Department of Medical Oncology, Dermatology, and Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida-IRB Lleida, Lleida, Spain.
Marti
Rosa M
RM
Yeramian
Andree
A
Sorolla
Anabel
A
Dolcet
Xavier
X
Llobet
David
D
Abal
Leandro
L
Santacana
Maria
M
Pallares
Judit
J
Llombart-Cussac
Antonio
A
Matias-Guiu
Xavier
X
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics
D000970:Antineoplastic Agents